PW

Paul Wotton

Cynata Therapeutics Limited | Non-Executive Director
Mr Wotton is the Executive Chairman of the Biotech LaunchPad at Rice University, Houston. He was President and CEO of Obsidian Therapeutics, Founding CEO of Sigilon Therapeutics (acquired by Lilly) and President and CEO of Ocata Therapeutics, Inc. (NASDAQ: OCAT) which was acquired by Astellas in 2016. Prior to Ocata, Dr Wotton had served as President and CEO of Antares Pharma Inc. (NASDAQ: ATRS). Prior to joining Antares, Dr Wotton was the CEO of Topigen Pharmaceuticals. Earlier in his career, he held senior level executive positions at SkyePharma plc, Eurand International BV, Penwest Pharmaceuticals, Abbott Laboratories and Merck, Sharp and Dohme. Dr Wotton is a member of the board of Vericel Corporation (NASDAQ: VCEL), Chairman of Dimension Inx., and Chairman of Kytopen Inc.

Company and Role

Company
Title
Tenure
Since
CYP
CYP
Cynata Therapeutics Limited
  • Non-Executive Director
10yrs, 1mthJun 2016

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
CYP
CYP
Cynata Therapeutics Limited
29/11/250585,076220,000N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
CYP
CYP
Cynata Therapeutics Limited
20/02/25
Exercise
69,767$0.300$20,930Exercise of options
CYP
CYP
Cynata Therapeutics Limited
20/02/25
Buy
69,767$0.300$20,930Exercise of options
CYP
CYP
Cynata Therapeutics Limited
23/01/25
Issued
200,000$0.180$36,000Placement
CYP
CYP
Cynata Therapeutics Limited
23/01/25
Transfer
139,534$0.205$28,604As advised by the company
CYP
CYP
Cynata Therapeutics Limited
23/01/25
Transfer
139,534$0.205$28,604As advised by the company